January 14, 2021 -- Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per a new research collaboration.
Developed with pathology datasets and machine-learning methods, the Nucleai platform may be used to help identify biomarkers for response.
The biomarkers allow further stratification of patient populations between responders and nonresponders, improve the success rate of clinical trials, and shorten time-to-market for pharmaceutical treatments, the companies said in a statement.
The research agreement includes an undisclosed upfront payment to Nucleai and milestone payments related to progress in clinical studies and development of companion diagnostics.
Copyright © 2021 scienceboard.net